Key Financial Metrics in the Earnings Conference Call Transcript:
1. Double-digit global revenue growth in the third quarter
2. Strong demand for Software-as-a-Service and new mask products
3. Non-GAAP net operating profit growth of 13% year-on-year
4. Diluted EPS of $0.71 on a non-GAAP basis
5. Double-digit revenue growth in the Americas region
6. 12% growth in mask and accessories sales in EMEA and APAC regions
7. Over 3 million patients monitored with 100% cloud-connected medical devices
8. EMEA and APAC regions saw solid growth in AirSense 10 range of devices
9. Annual Mobile Health report named ResMed as a key global leader in remote patient monitoring
10. Study showed ASV therapy significantly improves adherence for patients with treatment-emergent central sleep apnea

Overall, the company is experiencing strong growth in revenue, especially in the Americas, EMEA, and APAC regions. The focus on connected care and digital health is driving patient engagement and improving outcomes. The launch of innovative products such as the ResMed AirMini is expected to further drive growth in the future. Adopting an 'overweight' investment stance is recommended based on the company's financial performance and strategic initiatives.